6,700 Shares of Danaher Corporation $DHR Bought by David J Yvars Group

David J Yvars Group purchased a new stake in Danaher Corporation (NYSE:DHR) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 6,700 shares of the conglomerate’s stock, valued at approximately $1,484,000. Danaher makes up approximately 0.7% of David J Yvars Group’s investment portfolio, making the stock its 22nd largest holding.

Other hedge funds and other institutional investors have also made changes to their positions in the company. BlackRock Inc. purchased a new stake in shares of Danaher during the second quarter worth approximately $10,492,520,000. Jupiter Topco LLC purchased a new position in Danaher in the second quarter worth approximately $1,456,317,000. Generation Investment Management LLP acquired a new position in Danaher during the 2nd quarter worth approximately $1,287,949,000. Bank of America Corp DE acquired a new position in Danaher during the 2nd quarter worth approximately $993,846,000. Finally, Legal & General Group Plc purchased a new stake in shares of Danaher in the 2nd quarter valued at approximately $801,056,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on DHR. Royal Bank Of Canada lifted their price objective on shares of Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research report on Monday. UBS Group started coverage on Danaher in a research note on Wednesday, September 9th. They issued a “buy” rating and a $250.00 price target on the stock. Stifel Nicolaus lowered their price objective on Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. Weiss Ratings raised Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, September 16th. Finally, Evercore reaffirmed an “outperform” rating and issued a $230.00 price target on shares of Danaher in a report on Monday, July 6th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $235.23.

Danaher Stock Performance

DHR traded up $2.69 on Friday, reaching $220.15. The company had a trading volume of 3,934,329 shares, compared to its average volume of 4,457,726. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The stock has a market capitalization of $154.76 billion, a PE ratio of 39.10, a P/E/G ratio of 2.72 and a beta of 0.76. The stock has a 50-day moving average price of $210.88 and a 200-day moving average price of $194.44.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The company had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same quarter last year, the company posted $0.77 earnings per share. The business’s quarterly revenue was up 5.5% compared to the same quarter last year. As a group, research analysts forecast that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 annualized dividend and a yield of 0.7%. Danaher’s payout ratio is 28.42%.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.